A probe identifying CBL2, the human cellular homolog of the murine oncogene v-cbl and murine cellular protooncogene Cbl-2, and panels of rodent × human somatic cell hybrids were used to study the relationship of this protooncogene to translocations associated with acute leukemia, lymphoma, and Ewing sarcoma. CBL2 was mapped to 11 q23 and found to translocate from chromosome 11 to 4 in an acute leukemia cell line possessing a t(4; 11 )(q21 ;q23) and from chromosome 11 to 14 in a B-cell lymphoma with a t(11;14)(q23;q32). In an Ewing sarcoma cell line with a t(11;22)(q23;q12), however, CBL2 remained on chromosome 11. Additional studies of other genes in the region of 11q23 allowed the following ordering of these genes and breakpoints: 11cen – q23 – NCAM – CD3(E-D-G) – [t( 11; 14), t(4; 11)] – (THY1 CBL2, ETS1) – t( 11 ;22) -11 qter. The gross structure of the CBL2 sequences examined was not altered by either of the flanking breakpoints. Given that the 5’ and 3’ ends of the CBL2 gene are not known and are probably not evaluated by the v-cbl probe, these results do not rule out the possibility of CBL2 involvement in the pathogenesis of a subset of acute leukemias possessing a t(4;11), B-cell lymphomas possessing a t(11;14), or Ewing sarcomas posse
展开▼
